# Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

> **NCT00092482** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3882 (actual)

## Conditions studied

- Cervical Cancer
- Genital Warts

## Interventions

- **BIOLOGICAL:** V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years

## Key facts

- **NCT ID:** NCT00092482
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06-28
- **Primary completion:** 2004-06-30
- **Final completion:** 2008-08-15
- **Target enrollment:** 3882 (ACTUAL)
- **Last updated:** 2017-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092482, "Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00092482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*